AI assistant
Qiagen N.V. — Earnings Release 2019
Jul 25, 2019
Preview isn't available for this file type.
Download source filetitle: "Contacts:"
author: "John Gilardi"
date: 2019-07-24 19:12:00+00:00
processing_status: success_python-docx_mammoth
Key word(s): China restructuring; revised outlook
Ad hoc Announcement according to Art. 17 Market Abuse Regulation
QIAGEN’s Q2 2019 results in line with CER outlook, revised 2019 outlook due to intended restructuring of China NGS partnership
Venlo, The Netherlands, July 24, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announces that it achieved the outlook set for net sales growth and adjusted earnings per share at constant exchange rates (CER) for the second quarter of 2019.
As a result of the intention to restructure its next-generation sequencing (NGS) partnership in China, QIAGEN now expects full-year 2019 net sales growth of approximately 5-6% CER (previously about 7-8% CER) and adjusted diluted EPS of approximately $1.42-1.44 CER per share (previously about $1.45-1.47 CER). For the third quarter of 2019, QIAGEN expects net sales to grow approximately 4-5% CER. Adjusted diluted EPS is expected to be about $0.35-0.36 CER per share.
QIAGEN intends to restructure the current format of its NGS partnership in China due to the slower-than-expected uptake of invitro diagnostic clinical sequencing in this country. Sales from this partnership were planned to be approximately $30 million for full-year 2019, and weighted primarily to the second half of this year.
QIAGEN N.V.
Hulsterweg 82
5912 PL Venlo
The Netherlands
ISIN: NL0012169213
Frankfurt Stock Exchange, Regulated Market (Prime Standard)
Contacts QIAGEN N.V.:
Corporate Communications
John Gilardi, Tel: +49 2103 29 11711; [email protected]
Thomas Theuringer, Tel: +49 2013 29 11826 [email protected]